Measures – Talk Bio

Sarepta Pursues Efficiency Measures Amid $1 Billion Debt Due in 2027

1 month ago talkbio0Tagged 2025, debt, decline, Efficiency, ELEVIDYS, Financial cost, financial results, Financial savings, Measures, Muscular Dystrophy, Duchenne, restructuring, United States Food and Drug Administration

Sarepta Therapeutics; debt 2027; efficiency measures; ELEVIDYS; cost savings; restructuring; financial results 2025; FDA; Duchenne muscular dystrophy; stock decline

Neurogene Details New Safety Measures After Young Patient’s Death in Rett Syndrome AAV Gene Therapy Trial

4 months ago talkbio0Tagged AAVS1 gene, ASGCT, Clinical Trials, Dosage, gene therapy, Individual Adjustment, Lymphohistiocytosis, Hemophagocytic, Measures, MECP2 gene, Neurogene, NGN-401, Rett Syndrome, Safety, United States Food and Drug Administration

Neurogene; AAV gene therapy; Rett syndrome; NGN-401; ASGCT; safety measures; HLH; clinical trial; MECP2 gene; FDA; dose adjustment

Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits

1 year ago talkbio0Tagged Biological Factors, CBER, healthcare innovation, Measures, Medical Devices, Peter Marks, Prophylactic behavior, public health medicine (field), Regulatory Affairs, United States Food and Drug Administration, Vaccines

CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.

CSL Vifor’s Corrective Marketing Initiative to Address Anti-Competitive Concerns

1 year ago talkbio0Tagged anti-competitive practices, competition, Corrective, CSHL1 gene, Drug Industry, fairness, Market, Measures, Vifor

CSL Vifor, marketing campaign, anti-competitive practices, competition law, corrective measures, pharmaceutical industry, competition watchdog, market fairness.